PLATELET TRANSFUSION REFRACTORINESS (PTR)

Clinical trials for PLATELET TRANSFUSION REFRACTORINESS (PTR) explained in plain language.

Never miss a new study

Get alerted when new PLATELET TRANSFUSION REFRACTORINESS (PTR) trials appear

Sign up with your email to follow new studies for PLATELET TRANSFUSION REFRACTORINESS (PTR), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo may fix dangerous transfusion problem in blood cancer patients

Disease control Not yet recruiting

This study tests whether a drug called acalabrutinib, alone or with bortezomib, can reduce harmful antibodies that make platelet transfusions ineffective in people with blood cancers. About 42 adults aged 18-65 who have this transfusion problem will be enrolled. The goal is to im…

Matched conditions: PLATELET TRANSFUSION REFRACTORINESS (PTR)

Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

PLATELET TRANSFUSION REFRACTORINESS (PTR)

Get alerted when new PLATELET TRANSFUSION REFRACTORINESS (PTR) trials appear

New drug combo may fix dangerous transfusion problem in blood cancer patients